Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalind Rowland

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Review of Vaccines|May 25, 2011
Tuberculosis vaccines in clinical trialsRosalind Rowland, Helen McShane
Acute Medicine|August 12, 2024
Guest Editorial - Ambulatory Care: Turning Urgent and Emergency Care inside outRosalind Rowland, Daniel Lasserson
Clinical and Vaccine Immunology : CVI|May 21, 2010
Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85ASimone C de Cassan, Ansar A Pathan, Clare R Sander, et al.
Vaccine|December 26, 2012
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal deliveryJoel Meyer, Stephanie A Harris, Iman Satti, et al.
Plos One|July 12, 2013
Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85AMagali Matsumiya, Elena Stylianou, Kristin Griffiths, et al.
Vaccine|July 14, 2012
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsAnsar A Pathan, Angela M Minassian, Clare R Sander, et al.
The Lancet. Infectious Diseases|August 25, 2014
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trialIman Satti, Joel Meyer, Stephanie A Harris, et al.
Human Vaccines & Immunotherapeutics|June 5, 2013
Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccinesRosalind Rowland, Geraldine A O'Hara, Matthew Hamill, et al.
Clinical and Translational Science|August 14, 2012
Incidental diagnosis in healthy clinical trial subjectsChristopher J A Duncan, Rosalind Rowland, Patrick J Lillie, et al.
Vaccine|April 20, 2011
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccineDavid W Porter, Fiona M Thompson, Tamara K Berthoud, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Review of Vaccines|May 25, 2011
Tuberculosis vaccines in clinical trialsRosalind Rowland, Helen McShane
Acute Medicine|August 12, 2024
Guest Editorial - Ambulatory Care: Turning Urgent and Emergency Care inside outRosalind Rowland, Daniel Lasserson
Clinical and Vaccine Immunology : CVI|May 21, 2010
Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85ASimone C de Cassan, Ansar A Pathan, Clare R Sander, et al.
Vaccine|December 26, 2012
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal deliveryJoel Meyer, Stephanie A Harris, Iman Satti, et al.
Plos One|July 12, 2013
Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85AMagali Matsumiya, Elena Stylianou, Kristin Griffiths, et al.
Vaccine|July 14, 2012
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsAnsar A Pathan, Angela M Minassian, Clare R Sander, et al.
The Lancet. Infectious Diseases|August 25, 2014
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trialIman Satti, Joel Meyer, Stephanie A Harris, et al.
Human Vaccines & Immunotherapeutics|June 5, 2013
Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccinesRosalind Rowland, Geraldine A O'Hara, Matthew Hamill, et al.
Clinical and Translational Science|August 14, 2012
Incidental diagnosis in healthy clinical trial subjectsChristopher J A Duncan, Rosalind Rowland, Patrick J Lillie, et al.
Vaccine|April 20, 2011
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccineDavid W Porter, Fiona M Thompson, Tamara K Berthoud, et al.
Pageof 2